Showing 1611-1620 of 1735 results for "".
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-fulfills-post-marketing-approval-requirements-for-resure-sealant/2479164/Ocular Therapeutix has received notification from the FDA confirming it has fulfilled all post-approval study requirements for ReSure Sealant, with a requirement to update the ReSure label reflecting the study results. As a condition for ReSure’s pre-market approval application (PMA) in 2014, the
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/gyroscope-therapeutics-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2479087/Gyroscope Therapeutics announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) in the United States. All American Depositary Shares (ADSS) to be sold in the proposed IPO will be
- New Educational Resource On Importance of Eye Protection in Sports/Recreational Activititeshttps://modernod.com/news/new-educational-resource-on-importance-of-eye-protection-in-sports-recreational-activitites/2479046/The International Sports Vision Association (ISVA) and Zyloware Eyewear announced the launch of Protect. Prevent. Play., a new educational resource designed to help eye care professionals educate parents, coaches, teachers, athletic trainers and athletes of all ages and skill levels abou
- Allergan Launches Refresh Digital Lubricant Eye Dropshttps://modernod.com/news/abbvie-launches-refresh-digital-lubricant-eye-drops/2478901/Allergan announced the over-the-counter (OTC) launch of Refresh Digital, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. Refresh Digital features proprietary HydroCell technology that supports all three layers of the te
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- Pacific Vision Surgery Center Opens Doors to Bay Area Communityhttps://modernod.com/news/pacific-vision-surgery-center-opens-doors-to-bay-area-community/2478751/Pacific Vision Foundation has announced the opening of the new Pacific Vision Surgery Center. This state-of-the-art surgical facility is the manifestation of Pacific Vision Foundation’s mission to make excellent eye care available for all, regardless of ability to pay, while training the next gen
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr